Invesco Ltd. Takes $5.08 Million Position in Delcath Systems, Inc. $DCTH

Key Points

• Invesco Ltd. has made a new investment of approximately $5.08 million in Delcath Systems, acquiring 399,389 shares and now holds about 1.19% of the company.
• Delcath Systems' stock received both positive and negative ratings from analysts, with a consensus "Buy" rating and a target price of $24.50, while one firm downgraded it to "hold."
• The company reported earnings of $0.07 per share, exceeding expectations, with revenue of $24.16 million for the last quarter, surpassing the consensus estimate.

Invesco Ltd. purchased a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 399,389 shares of the company's stock, valued at approximately $5,084,000. Invesco Ltd. owned approximately 1.19% of Delcath Systems as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Quarry LP bought a new position in shares of Delcath Systems during the fourth quarter valued at about $34,000. Inlight Wealth Management LLC purchased a new position in shares of Delcath Systems during the first quarter valued at approximately $85,000. NBC Securities Inc. lifted its holdings in shares of Delcath Systems by 99,900.0% during the first quarter. NBC Securities Inc. now owns 10,000 shares of the company's stock valued at $127,000 after purchasing an additional 9,990 shares during the last quarter. Graham Capital Management L.P. purchased a new stake in Delcath Systems during the 4th quarter valued at about $123,000. Finally, PharVision Advisers LLC purchased a new position in Delcath Systems in the 4th quarter worth approximately $129,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Stock Down 1.1%

Delcath Systems stock traded down $0.12 during midday trading on Tuesday, reaching $10.90. The stock had a trading volume of 445,614 shares, compared to its average volume of 783,744. Delcath Systems, Inc. has a 52-week low of $8.08 and a 52-week high of $18.23. The firm has a market cap of $381.28 million, a price-to-earnings ratio of 218.00 and a beta of 0.85. The company has a fifty day moving average of $11.41 and a 200 day moving average of $12.98.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $24.16 million for the quarter, compared to analyst estimates of $22.84 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%. Equities research analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Delcath Systems from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Wall Street Zen cut Delcath Systems from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Finally, Stephens reissued an "overweight" rating and set a $25.00 price target on shares of Delcath Systems in a report on Monday, June 23rd. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Delcath Systems has an average rating of "Buy" and a consensus price target of $24.50.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.